18 and older, any sex, with Refractory Multiple Myeloma or Relapse Multiple Myeloma. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
The Number of Patients With 12-month Progression-free Survival.Primary· 12 months
The primary endpoint of the study is the 12-month progression-free survival (PFS) with time counted from the CAR-T infusion conditional on being alive and progression-free at day +90 post CAR-T. An event will be defined as documented progression or death for any cause, subjects without an event will be censored at the last date known to be alive without progression.
Group
Value
95% CI
Belantamab Mafodotin
1
Adverse events — posted to ClinicalTrials.gov
Time frame: 15 months.
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
Belantamab Mafodotin
Serious: 0/1 (0%)
Deaths: 0/1
Other adverse events (28 terms — click to expand)
Reaction
System
Belantamab Mafodotin
acquired torsion dystonia
Musculoskeletal and connective tissue disorders
—
Anemia
Blood and lymphatic system disorders
—
Back Pain
Musculoskeletal and connective tissue disorders
—
Blood lactate dehydrogenase increased
Investigations
—
Blurred Vision, Right eye
Eye disorders
—
Cervical dystonia
Musculoskeletal and connective tissue disorders
—
Cholesterol high
Investigations
—
Corn, Left plantat feet
Skin and subcutaneous tissue disorders
—
Corneal Stromal scar, both eyes
Eye disorders
—
Cough
Respiratory, thoracic and mediastinal disorders
—
Diarrhea
Gastrointestinal disorders
—
Dyspnea
Respiratory, thoracic and mediastinal disorders
—
Corneal toxicities
Eye disorders
—
Fever
General disorders
—
Genital Herpes
Infections and infestations
—
Headache
Nervous system disorders
—
Hypertension
Vascular disorders
—
Hypophosphatemia
Metabolism and nutrition disorders
—
Infertility
Reproductive system and breast disorders
—
Knee pain
General disorders
—
Lung Infection
Infections and infestations
—
Lymphocyte count decreased
Investigations
—
Nasal congestion
Respiratory, thoracic and mediastinal disorders
—
Platelet count decreased
Investigations
—
Insomnia
Psychiatric disorders
—
Skin papilloma
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
This is a multicenter phase II, open-label study evaluating the efficacy and safety of belantamab mafodotin maintenance in participants with relapsed and/or refractory multiple myeloma (RRMM) who have received commercially available anti-BCMA CAR-T-cell therapy. Subjects will be enrolled 60-130 days after chimeric antigen receptor T-cell therapy (CAR-T) and receive belantamab mafodotin as maintenance therapy. Each maintenance cycle will have a duration of 56 days (+/- three days) and belantamab mafodotin will be administered at a dose of 2.5 mg/kg IV on day 1 of each cycle.
Publications & conference data
6 peer-reviewed publications reference this trial (live from Europe PMC):
NCT07224672 — A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, an
· Phase 2
· not yet recruiting
NCT07227311 — A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants
· Phase 2
· not yet recruiting
NCT06679101 — A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab
· Phase 3
· recruiting
NCT05922501 — Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma
· Phase 2
· recruiting
NCT05714839 — A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monother
· Phase 1, PHASE2
· recruiting
Other recruiting trials for Refractory Multiple Myeloma
Currently open trials in the same condition.
NCT07181941 — Response-Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed, Refractory, or Triple-Class Relapsed/Refrac
· Phase 1, PHASE2
· recruiting
NCT07340853 — CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma
· Phase 1
· recruiting
NCT07093554 — Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patie
· Phase 1
· recruiting
NCT07045727 — Prehabilitation With Aerobic and Resistance Exercise for Improving Physical Fitness and Quality of Life Outcomes in Olde
· NA
· recruiting
NCT06348108 — Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma
· Phase 1
· recruiting
Other Medical College of Wisconsin trials
Trials by the same sponsor.
NCT07260552 — Rapid Engagement for Solutions to Population and Outcomes Through Networked Dialogue for Coronary Heart Disease
· not yet recruiting
NCT06795360 — Weight Changes After Incretin-mimetics
· NA
· not yet recruiting
NCT07228208 — Role of Endothelial Dysfunction on Exercise Pressor Reflex in Type 2 Diabetes
· NA
· not yet recruiting
NCT07298460 — Stimulation-based Therapy to Improve Balance in DCM
· Phase 1, PHASE2
· not yet recruiting
NCT07434544 — Cardiometabolic Effects of Non-Nutritive Sweeteners (NNS) in Type 1 Diabetes (T1D)
· NA
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Medical College of Wisconsin
Last refreshed: 28 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05117008.